Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Novo Nordisk Posts 138 Percent Rise In 4Q Profits

By Pharmaceutical Processing | January 29, 2009

COPENHAGEN, Denmark (AP) — Danish drug maker Novo Nordisk A/S on Thursday said fourth-quarter profits more than doubled on strong sales of insulin and other diabetes drugs as well as one-time costs a year earlier. The world’s top maker of insulin said net profit in the last three months of 2008 rose 138 percent to 2.3 billion kroner ($409 million), up from 977 million kroner in the same period in 2007. Quarterly sales rose 15 percent to 12.6 billion kroner from 10.9 billion kroner in the previous year. Sales in North America increased 24 percent, boosted by a rebate reversal related to a federal health care program and wholesalers building up stocks, Novo Nordisk said. However, the main reason for the higher net profit was that Novo Nordisk took a 1.3 billion kroner hit in the fourth quarter of 2007 from scrapping an inhaled insulin project, chief financial officer Jesper Brandgaard told The Associated Press. Brandgaard also said “a positive currency effect” helped this year’s results.Novo Nordisk shares rose 5.5 percent to 299 kroner ($53.13) in Copenhagen. Full-year net profit increased 13 percent to 9.6 billion kroner, while sales rose 11 percent to 45.5 billion kroner. “We are satisfied with the solid business results achieved in 2008 driven by the continued penetration of our modern insulins in all key markets,” chief executive Lars Rebien Soerensen said. He said Novo Nordisk expects double-digit growth in sales and operating profit this year despite the economic downturn. The Copenhagen-based company has about 26,500 employees in 80 countries.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE